Evaluation of anti-nucleocapsid level variation to assess SARS-CoV-2 seroprevalence in a vaccinated population-Reference-Cited by-同舟云学术

Evaluation of anti-nucleocapsid level variation to assess SARS-CoV-2 seroprevalence in a vaccinated population

Published:2023-04-11 Issue:6 Volume:55 Page:425-430
ISSN:2374-4235
Container-title:Infectious Diseases
language:en
Short-container-title:Infectious Diseases

Author:

Bazin Renée¹^ORCID,Rochette Samuel²,Perreault Josée¹,Fournier Marie-Josée¹,Grégoire Yves¹^ORCID,Boivin Amélie²,Lewin Antoine²³^ORCID,Germain Marc¹^ORCID,Renaud Christian²⁴^ORCID

Affiliation:

1. Affaires Médicales et Innovation, Héma-Québec, Québec, Canada

2. Affaires Médicales et Innovation, Héma-Québec, Montréal, Canada

3. Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Canada

4. Département de microbiologie, CHU Sainte-Justine, Université de Montréal, Montréal, Canada

Funder

Ministère de la Santé et des Services Sociaux (MSSS) du Québec

Public Health Agency of Canada

Publisher

Informa UK Limited

Subject

Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/23744235.2023.2195938

Reference21 articles.

1. Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals

2. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial

3. Epidemiological and Serological Analysis of a SARS-CoV-2 Outbreak in a Nursing Home: Impact of SARS-CoV-2 Vaccination and Enhanced Neutralizing Immunity Following Breakthrough Infection

4. Outbreak of SARS-CoV-2 Lineage 20I/501Y.V1 in a Nursing Home Underlines the Crucial Role of Vaccination in Both Residents and Staff

5. EUA Authorized Serology Test Performance_FDA.pdf. Available from: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence of SARS-CoV-2 during the Omicron wave: Results of a longitudinal serosurvey in Québec, Canada;Canadian Journal of Public Health;2024-07-26

2. SARS‐CoV‐2 immunoassays in a predominantly vaccinated population: Performances and qualitative agreements obtained with two analytical approaches and four immunoassays;Vox Sanguinis;2024-04-05

3. Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine;npj Vaccines;2024-02-21

4. Enhancing detection of SARS-CoV-2 re-infections using longitudinal sero-monitoring: demonstration of a methodology in a cohort of people experiencing homelessness in Toronto, Canada;BMC Infectious Diseases;2024-02-02

5. Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine;Viruses;2023-09-15